2024 forecast: As CDMOs come off pandemic's highs and lows, employment and funding hitches persist - Fierce Pharma

Even after the heady highs of the COVID-19 era, the contract development and manufacturing organization (CDMO) realm remains one of biopharma's buzziest fields. This article gives a forecast, covering opportunities and obstacles for 2024 as contract manufacturers increasingly become vital partners for producing new complex therapeutics. Read the article here and hear what our colleagues have to say.